Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
CAMBRIDGE, Mass., Sept. 22, 2017 -- Acer Therapeutics Inc., (Nasdaq:ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and ultra-rare diseases with critical unmet medical need, today announced that Chris Schelling, Chief Executive Officer and Founder, will provide a corporate overview at the Cantor Fitzgerald Global Healthcare Conference, being held September 25-27, 2017 in New York City.
| Acer Therapeutics Conference Presentation Details | ||
| Date: | Tuesday, September 26 | |
| Time: | 8:00 am Eastern Time | |
| Location: | InterContinental New York Barclay Hotel, Rockefeller Room | |
| Webcast: | https://acertx.com/investor-relations/events-presentations/ | |
About Acer Therapeutics
Acer, headquartered in Cambridge, MA, is a pharmaceutical company that acquires, develops and intends to commercialize therapies for patients with serious rare and ultra-rare diseases with critical unmet medical need. Acer’s late-stage clinical pipeline includes two candidates for severe genetic disorders for which there are few or no FDA-approved treatments: EDSIVO™ (celiprolol) for vEDS, and ACER-001 (a fully taste-masked, immediate release formulation of sodium phenylbutyrate) for urea cycle disorders (UCD) and Maple Syrup Urine Disease (MSUD). There are no FDA-approved drugs for vEDS and MSUD and limited options for UCD, which collectively impact more than 4,000 patients in the United States. Acer’s products have clinical proof-of-concept and mechanistic differentiation, and Acer intends to seek approval for them in the U.S. by using the regulatory pathway established under section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act, or FFDCA, that allows an applicant to rely for approval at least in part on third-party data, which is expected to expedite the preparation, submission, and approval of a marketing application.
For more information, visit www.acertx.com.
Contact:
Hans Vitzthum
LifeSci Advisors, LLC
212-915-2568
[email protected]
